Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lung Neoplasms | 27 | 2022 | 625 | 7.530 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 19 | 2021 | 316 | 6.400 |
Why?
|
Biomarkers, Tumor | 11 | 2022 | 175 | 4.450 |
Why?
|
Autoantibodies | 5 | 2021 | 100 | 2.080 |
Why?
|
Multiple Pulmonary Nodules | 3 | 2022 | 9 | 1.980 |
Why?
|
Insulin-Like Growth Factor I | 5 | 2022 | 54 | 1.320 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2017 | 184 | 1.240 |
Why?
|
Immunoassay | 3 | 2018 | 41 | 1.190 |
Why?
|
Biomarkers | 8 | 2022 | 689 | 1.160 |
Why?
|
Insulin-Like Growth Factor Binding Proteins | 3 | 2015 | 11 | 1.060 |
Why?
|
Solitary Pulmonary Nodule | 2 | 2015 | 11 | 0.990 |
Why?
|
Drug Resistance, Neoplasm | 3 | 2020 | 75 | 0.960 |
Why?
|
Adenocarcinoma | 5 | 2018 | 189 | 0.940 |
Why?
|
Prognosis | 9 | 2022 | 840 | 0.920 |
Why?
|
Early Detection of Cancer | 5 | 2022 | 79 | 0.840 |
Why?
|
Humans | 45 | 2022 | 29337 | 0.830 |
Why?
|
Cachexia | 2 | 2019 | 11 | 0.780 |
Why?
|
Antineoplastic Agents, Immunological | 1 | 2021 | 18 | 0.780 |
Why?
|
Lymphoma, Non-Hodgkin | 2 | 2019 | 42 | 0.770 |
Why?
|
Immunotherapy | 1 | 2021 | 62 | 0.770 |
Why?
|
Aged, 80 and over | 12 | 2018 | 4851 | 0.710 |
Why?
|
HLA Antigens | 2 | 2021 | 17 | 0.700 |
Why?
|
Erlotinib Hydrochloride | 2 | 2020 | 16 | 0.700 |
Why?
|
Middle Aged | 18 | 2021 | 9823 | 0.690 |
Why?
|
Algorithms | 7 | 2022 | 400 | 0.680 |
Why?
|
Neoplasm Staging | 6 | 2021 | 340 | 0.660 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2018 | 13 | 0.650 |
Why?
|
Syndecan-1 | 1 | 2018 | 8 | 0.650 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2018 | 19 | 0.650 |
Why?
|
Aged | 18 | 2019 | 9448 | 0.640 |
Why?
|
Vimentin | 2 | 2016 | 2 | 0.640 |
Why?
|
Neovascularization, Pathologic | 2 | 2015 | 56 | 0.630 |
Why?
|
Nerve Growth Factors | 1 | 2018 | 44 | 0.620 |
Why?
|
Inflammation Mediators | 1 | 2018 | 83 | 0.620 |
Why?
|
Male | 22 | 2021 | 15621 | 0.600 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2017 | 24 | 0.600 |
Why?
|
Female | 22 | 2021 | 16197 | 0.590 |
Why?
|
Lymphatic Metastasis | 3 | 2012 | 81 | 0.570 |
Why?
|
Tandem Mass Spectrometry | 2 | 2013 | 26 | 0.570 |
Why?
|
Kidney Transplantation | 2 | 2016 | 125 | 0.560 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2017 | 290 | 0.560 |
Why?
|
Insulin-Like Growth Factor II | 1 | 2014 | 8 | 0.510 |
Why?
|
Graft Rejection | 2 | 2016 | 76 | 0.510 |
Why?
|
Cytokines | 2 | 2014 | 347 | 0.500 |
Why?
|
Predictive Value of Tests | 5 | 2014 | 521 | 0.490 |
Why?
|
Adult | 12 | 2018 | 8601 | 0.480 |
Why?
|
Adrenergic alpha-1 Receptor Antagonists | 1 | 2013 | 1 | 0.480 |
Why?
|
Doxazosin | 1 | 2013 | 3 | 0.480 |
Why?
|
Chloroquine | 1 | 2013 | 12 | 0.480 |
Why?
|
Melanins | 1 | 2013 | 11 | 0.480 |
Why?
|
Immunoglobulin G | 3 | 2022 | 129 | 0.470 |
Why?
|
Sulfonamides | 1 | 2013 | 54 | 0.460 |
Why?
|
Interleukin-2 Receptor alpha Subunit | 1 | 2013 | 7 | 0.460 |
Why?
|
Multivariate Analysis | 4 | 2017 | 324 | 0.440 |
Why?
|
Immunoglobulin M | 2 | 2022 | 19 | 0.440 |
Why?
|
Cohort Studies | 6 | 2019 | 1939 | 0.430 |
Why?
|
C-Peptide | 1 | 2011 | 7 | 0.420 |
Why?
|
Retrospective Studies | 7 | 2019 | 3273 | 0.410 |
Why?
|
Sensitivity and Specificity | 3 | 2022 | 553 | 0.410 |
Why?
|
Cell Line, Tumor | 7 | 2020 | 264 | 0.400 |
Why?
|
Blood Chemical Analysis | 1 | 2010 | 13 | 0.390 |
Why?
|
Hematologic Tests | 1 | 2010 | 6 | 0.380 |
Why?
|
Protein Array Analysis | 1 | 2010 | 10 | 0.380 |
Why?
|
Survival Analysis | 3 | 2021 | 298 | 0.380 |
Why?
|
Protein Kinase Inhibitors | 3 | 2020 | 47 | 0.380 |
Why?
|
ErbB Receptors | 4 | 2020 | 72 | 0.360 |
Why?
|
Area Under Curve | 4 | 2014 | 66 | 0.350 |
Why?
|
Lymph Nodes | 1 | 2009 | 70 | 0.330 |
Why?
|
Disease-Free Survival | 3 | 2017 | 175 | 0.330 |
Why?
|
Risk Assessment | 4 | 2017 | 679 | 0.300 |
Why?
|
Antigens, Neoplasm | 2 | 2021 | 37 | 0.290 |
Why?
|
Treatment Outcome | 5 | 2021 | 3478 | 0.290 |
Why?
|
Diagnosis, Differential | 2 | 2018 | 389 | 0.270 |
Why?
|
Antibodies, Viral | 2 | 2022 | 87 | 0.260 |
Why?
|
Proteomics | 2 | 2018 | 91 | 0.240 |
Why?
|
Animals | 11 | 2020 | 4552 | 0.240 |
Why?
|
Young Adult | 4 | 2018 | 1932 | 0.240 |
Why?
|
ROC Curve | 2 | 2014 | 138 | 0.230 |
Why?
|
Pneumonectomy | 2 | 2017 | 67 | 0.230 |
Why?
|
Survival Rate | 2 | 2018 | 349 | 0.230 |
Why?
|
Chondrocytes | 3 | 2014 | 197 | 0.230 |
Why?
|
Reproducibility of Results | 3 | 2014 | 788 | 0.230 |
Why?
|
Immunoglobulin E | 1 | 2022 | 15 | 0.220 |
Why?
|
Vaccines | 1 | 2022 | 12 | 0.220 |
Why?
|
Immunoglobulin A | 1 | 2022 | 19 | 0.220 |
Why?
|
Mutation | 3 | 2020 | 383 | 0.220 |
Why?
|
Complement C1q | 1 | 2022 | 3 | 0.220 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2016 | 200 | 0.220 |
Why?
|
Sarcopenia | 2 | 2019 | 26 | 0.220 |
Why?
|
Seroconversion | 1 | 2022 | 1 | 0.220 |
Why?
|
Insulin-Like Growth Factor Binding Protein 3 | 1 | 2022 | 6 | 0.220 |
Why?
|
Spike Glycoprotein, Coronavirus | 1 | 2022 | 17 | 0.210 |
Why?
|
Organoids | 1 | 2021 | 8 | 0.210 |
Why?
|
Precision Medicine | 1 | 2021 | 24 | 0.200 |
Why?
|
Follow-Up Studies | 2 | 2018 | 1830 | 0.200 |
Why?
|
Neoplasm Invasiveness | 3 | 2017 | 68 | 0.200 |
Why?
|
Colorectal Neoplasms | 1 | 2022 | 82 | 0.200 |
Why?
|
Neoplasms | 2 | 2021 | 247 | 0.200 |
Why?
|
B7-H1 Antigen | 1 | 2021 | 13 | 0.200 |
Why?
|
Pilot Projects | 1 | 2022 | 394 | 0.200 |
Why?
|
Proportional Hazards Models | 3 | 2017 | 340 | 0.200 |
Why?
|
Programmed Cell Death 1 Receptor | 1 | 2021 | 18 | 0.200 |
Why?
|
Bone Morphogenetic Protein 7 | 2 | 2011 | 62 | 0.200 |
Why?
|
Observer Variation | 1 | 2021 | 118 | 0.190 |
Why?
|
Endothelin-1 | 1 | 2020 | 8 | 0.190 |
Why?
|
Biochemistry | 1 | 2000 | 1 | 0.190 |
Why?
|
Tomography, X-Ray Computed | 2 | 2015 | 770 | 0.190 |
Why?
|
Mass Screening | 1 | 2022 | 177 | 0.190 |
Why?
|
Disease Progression | 2 | 2014 | 787 | 0.190 |
Why?
|
Weight Loss | 2 | 2019 | 99 | 0.180 |
Why?
|
Proteins | 1 | 2000 | 72 | 0.180 |
Why?
|
Prospective Studies | 2 | 2018 | 1811 | 0.180 |
Why?
|
Receptors, CXCR | 1 | 2019 | 1 | 0.180 |
Why?
|
Esophagectomy | 1 | 2019 | 21 | 0.180 |
Why?
|
Epithelial-Mesenchymal Transition | 2 | 2019 | 5 | 0.180 |
Why?
|
Protein Binding | 3 | 2014 | 127 | 0.180 |
Why?
|
Patient Selection | 1 | 2021 | 232 | 0.170 |
Why?
|
Esophageal Neoplasms | 1 | 2019 | 45 | 0.170 |
Why?
|
RNA, Small Untranslated | 1 | 2018 | 1 | 0.170 |
Why?
|
Channelopathies | 1 | 2018 | 7 | 0.170 |
Why?
|
Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels | 1 | 2018 | 18 | 0.160 |
Why?
|
Carcinoma, Large Cell | 1 | 2018 | 15 | 0.160 |
Why?
|
CA1 Region, Hippocampal | 1 | 2018 | 17 | 0.160 |
Why?
|
Cell Movement | 2 | 2016 | 105 | 0.160 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2016 | 100 | 0.160 |
Why?
|
Neuronal Plasticity | 1 | 2018 | 43 | 0.160 |
Why?
|
Pyramidal Cells | 1 | 2018 | 44 | 0.160 |
Why?
|
SOS1 Protein | 1 | 2016 | 4 | 0.150 |
Why?
|
Proto-Oncogene Proteins c-cbl | 1 | 2016 | 12 | 0.150 |
Why?
|
rac1 GTP-Binding Protein | 1 | 2016 | 12 | 0.150 |
Why?
|
Kidney Tubules | 1 | 2016 | 10 | 0.150 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2018 | 178 | 0.140 |
Why?
|
Muscle, Skeletal | 1 | 2019 | 349 | 0.140 |
Why?
|
Adaptor Proteins, Vesicular Transport | 1 | 2016 | 42 | 0.140 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2016 | 75 | 0.140 |
Why?
|
Cattle | 2 | 2013 | 217 | 0.140 |
Why?
|
Metformin | 1 | 2016 | 21 | 0.140 |
Why?
|
Computational Biology | 2 | 2014 | 23 | 0.140 |
Why?
|
Hypoglycemic Agents | 1 | 2016 | 56 | 0.140 |
Why?
|
Mice, Transgenic | 4 | 2019 | 248 | 0.130 |
Why?
|
Protein-Arginine N-Methyltransferases | 1 | 2015 | 2 | 0.130 |
Why?
|
Repressor Proteins | 1 | 2015 | 29 | 0.130 |
Why?
|
Aggrecans | 2 | 2013 | 146 | 0.130 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2015 | 44 | 0.130 |
Why?
|
Oligonucleotide Array Sequence Analysis | 2 | 2011 | 58 | 0.130 |
Why?
|
Collagen Type X | 1 | 2014 | 2 | 0.130 |
Why?
|
Minnesota | 1 | 2014 | 8 | 0.130 |
Why?
|
Hematologic Neoplasms | 1 | 2014 | 17 | 0.130 |
Why?
|
Mice | 5 | 2020 | 1607 | 0.120 |
Why?
|
Kidney Failure, Chronic | 1 | 2016 | 161 | 0.120 |
Why?
|
Microspheres | 1 | 2014 | 32 | 0.120 |
Why?
|
Cell Differentiation | 1 | 2014 | 146 | 0.120 |
Why?
|
Choroid | 1 | 2013 | 3 | 0.120 |
Why?
|
Iris | 1 | 2013 | 3 | 0.120 |
Why?
|
Biological Assay | 1 | 2013 | 9 | 0.120 |
Why?
|
Retinal Pigment Epithelium | 1 | 2013 | 2 | 0.120 |
Why?
|
Illinois | 1 | 2014 | 241 | 0.120 |
Why?
|
Metabolic Syndrome | 1 | 2014 | 66 | 0.120 |
Why?
|
src-Family Kinases | 1 | 2013 | 8 | 0.120 |
Why?
|
Collagen Type IV | 2 | 2004 | 4 | 0.120 |
Why?
|
Reference Values | 1 | 2014 | 227 | 0.120 |
Why?
|
In Vitro Techniques | 1 | 2013 | 213 | 0.120 |
Why?
|
Feasibility Studies | 1 | 2014 | 227 | 0.120 |
Why?
|
Gene Expression Regulation | 2 | 2014 | 284 | 0.110 |
Why?
|
Chemokine CCL3 | 1 | 2013 | 12 | 0.110 |
Why?
|
Granuloma | 1 | 2013 | 13 | 0.110 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 1 | 2013 | 14 | 0.110 |
Why?
|
Chemokine CXCL12 | 1 | 2013 | 7 | 0.110 |
Why?
|
Chondroitin Sulfates | 1 | 2013 | 28 | 0.110 |
Why?
|
Respiratory Tract Infections | 1 | 2013 | 22 | 0.110 |
Why?
|
Cell Proliferation | 3 | 2021 | 201 | 0.110 |
Why?
|
Amino Acid Sequence | 5 | 2015 | 193 | 0.110 |
Why?
|
Interleukin-10 | 1 | 2013 | 36 | 0.110 |
Why?
|
Interleukin-1beta | 1 | 2013 | 55 | 0.110 |
Why?
|
Molecular Sequence Data | 5 | 2015 | 246 | 0.110 |
Why?
|
Postoperative Complications | 1 | 2019 | 957 | 0.110 |
Why?
|
Interleukin-6 | 1 | 2013 | 108 | 0.110 |
Why?
|
Decision Support Techniques | 1 | 2012 | 52 | 0.110 |
Why?
|
Pneumonia | 1 | 2013 | 67 | 0.110 |
Why?
|
Chronic Disease | 1 | 2014 | 495 | 0.100 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2013 | 215 | 0.100 |
Why?
|
Obesity | 1 | 2014 | 291 | 0.100 |
Why?
|
Transcriptome | 2 | 2022 | 83 | 0.100 |
Why?
|
Animal Experimentation | 1 | 2010 | 2 | 0.100 |
Why?
|
Electrophoresis, Gel, Two-Dimensional | 1 | 2010 | 9 | 0.100 |
Why?
|
Serum | 1 | 2010 | 9 | 0.100 |
Why?
|
Radiography | 1 | 2013 | 678 | 0.100 |
Why?
|
Antibodies, Neoplasm | 1 | 2010 | 10 | 0.100 |
Why?
|
Kaplan-Meier Estimate | 3 | 2017 | 162 | 0.090 |
Why?
|
Risk Factors | 2 | 2016 | 2443 | 0.090 |
Why?
|
Mass Spectrometry | 3 | 2014 | 41 | 0.080 |
Why?
|
Sodium Dodecyl Sulfate | 1 | 2008 | 3 | 0.080 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 1 | 2008 | 38 | 0.080 |
Why?
|
Case-Control Studies | 1 | 2010 | 638 | 0.080 |
Why?
|
Intervertebral Disc | 1 | 2010 | 212 | 0.080 |
Why?
|
Phosphoproteins | 1 | 2008 | 26 | 0.080 |
Why?
|
Alzheimer Disease | 2 | 2018 | 1942 | 0.080 |
Why?
|
Preoperative Care | 1 | 2009 | 135 | 0.080 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2020 | 24 | 0.080 |
Why?
|
Metals | 1 | 2008 | 160 | 0.080 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 3 | 2015 | 145 | 0.070 |
Why?
|
Signal Transduction | 3 | 2014 | 482 | 0.070 |
Why?
|
Cartilage, Articular | 1 | 2011 | 524 | 0.070 |
Why?
|
Melanoma | 2 | 2004 | 52 | 0.070 |
Why?
|
Metalloproteases | 1 | 2004 | 5 | 0.060 |
Why?
|
Hyaluronan Receptors | 1 | 2004 | 31 | 0.060 |
Why?
|
Peptide Fragments | 2 | 2004 | 99 | 0.060 |
Why?
|
Body Weight | 2 | 2017 | 133 | 0.060 |
Why?
|
Real-Time Polymerase Chain Reaction | 2 | 2015 | 47 | 0.060 |
Why?
|
Glycosylation | 1 | 2022 | 24 | 0.060 |
Why?
|
Antibody Formation | 1 | 2022 | 40 | 0.060 |
Why?
|
Adolescent | 1 | 2009 | 2279 | 0.060 |
Why?
|
Microsatellite Instability | 1 | 2022 | 6 | 0.050 |
Why?
|
Tumor Microenvironment | 1 | 2022 | 14 | 0.050 |
Why?
|
Proline | 1 | 2002 | 19 | 0.050 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2021 | 14 | 0.050 |
Why?
|
Fluorescence | 1 | 2021 | 12 | 0.050 |
Why?
|
Disease Models, Animal | 2 | 2018 | 724 | 0.050 |
Why?
|
Loss of Heterozygosity | 1 | 2021 | 4 | 0.050 |
Why?
|
Genomics | 1 | 2021 | 43 | 0.050 |
Why?
|
Biological Availability | 1 | 2020 | 26 | 0.050 |
Why?
|
Vasoconstriction | 1 | 2020 | 24 | 0.050 |
Why?
|
Base Sequence | 2 | 2014 | 134 | 0.050 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2020 | 65 | 0.050 |
Why?
|
Tumor Cells, Cultured | 2 | 2015 | 145 | 0.050 |
Why?
|
RNA, Messenger | 2 | 2015 | 323 | 0.050 |
Why?
|
beta-Arrestins | 1 | 2019 | 1 | 0.040 |
Why?
|
Neoplasms, Experimental | 1 | 2019 | 10 | 0.040 |
Why?
|
MAP Kinase Signaling System | 1 | 2019 | 38 | 0.040 |
Why?
|
Models, Biological | 1 | 2021 | 343 | 0.040 |
Why?
|
Body Composition | 1 | 2019 | 56 | 0.040 |
Why?
|
Antineoplastic Agents | 1 | 2020 | 218 | 0.040 |
Why?
|
Endoplasmic Reticulum | 1 | 2018 | 28 | 0.040 |
Why?
|
Sex Factors | 1 | 2019 | 496 | 0.040 |
Why?
|
Action Potentials | 1 | 2018 | 136 | 0.040 |
Why?
|
Leukocyte Count | 1 | 2017 | 92 | 0.040 |
Why?
|
Ubiquitination | 1 | 2016 | 9 | 0.040 |
Why?
|
Time-Lapse Imaging | 1 | 2016 | 8 | 0.040 |
Why?
|
Neoplasm Transplantation | 1 | 2016 | 23 | 0.040 |
Why?
|
A549 Cells | 1 | 2016 | 9 | 0.040 |
Why?
|
Lymphocytes | 1 | 2017 | 110 | 0.040 |
Why?
|
Fibrosis | 1 | 2016 | 39 | 0.040 |
Why?
|
Neoplasm Metastasis | 1 | 2016 | 101 | 0.040 |
Why?
|
Neutrophils | 1 | 2017 | 117 | 0.040 |
Why?
|
Atrophy | 1 | 2016 | 102 | 0.040 |
Why?
|
Graft Survival | 1 | 2016 | 98 | 0.030 |
Why?
|
Biopsy | 1 | 2016 | 234 | 0.030 |
Why?
|
Twist-Related Protein 1 | 1 | 2015 | 2 | 0.030 |
Why?
|
Fluorescent Antibody Technique, Indirect | 1 | 2015 | 6 | 0.030 |
Why?
|
Arginine | 1 | 2015 | 18 | 0.030 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2015 | 45 | 0.030 |
Why?
|
Cadherins | 1 | 2015 | 31 | 0.030 |
Why?
|
RNA, Small Interfering | 1 | 2015 | 64 | 0.030 |
Why?
|
Two-Hybrid System Techniques | 1 | 2014 | 3 | 0.030 |
Why?
|
Enhancer Elements, Genetic | 1 | 2014 | 11 | 0.030 |
Why?
|
Blotting, Western | 1 | 2015 | 170 | 0.030 |
Why?
|
Hypertrophy | 1 | 2014 | 19 | 0.030 |
Why?
|
Cyclooxygenase 2 | 1 | 2014 | 30 | 0.030 |
Why?
|
Lipid Metabolism | 1 | 2014 | 31 | 0.030 |
Why?
|
Binding Sites | 1 | 2014 | 71 | 0.030 |
Why?
|
Diabetes Mellitus | 1 | 2016 | 138 | 0.030 |
Why?
|
Nuclear Proteins | 1 | 2015 | 88 | 0.030 |
Why?
|
Genetic Association Studies | 1 | 2014 | 86 | 0.030 |
Why?
|
Insulin Resistance | 1 | 2014 | 60 | 0.030 |
Why?
|
DNA Methylation | 1 | 2015 | 124 | 0.030 |
Why?
|
Wound Healing | 1 | 2015 | 168 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2013 | 4 | 0.030 |
Why?
|
Protein Kinase C beta | 1 | 2013 | 7 | 0.030 |
Why?
|
Transcription Factors | 1 | 2014 | 156 | 0.030 |
Why?
|
Protein Structure, Secondary | 2 | 2004 | 19 | 0.030 |
Why?
|
Cell Adhesion | 2 | 2004 | 43 | 0.030 |
Why?
|
Ligands | 2 | 2004 | 55 | 0.030 |
Why?
|
Protein Kinase C | 1 | 2013 | 44 | 0.030 |
Why?
|
Enzyme Activation | 1 | 2013 | 109 | 0.030 |
Why?
|
Phosphorylation | 1 | 2013 | 159 | 0.030 |
Why?
|
Oligosaccharides | 1 | 2013 | 17 | 0.030 |
Why?
|
Reference Standards | 1 | 2013 | 33 | 0.030 |
Why?
|
Cell Survival | 1 | 2013 | 169 | 0.030 |
Why?
|
Cell Membrane | 1 | 2013 | 105 | 0.030 |
Why?
|
Least-Squares Analysis | 1 | 2011 | 8 | 0.030 |
Why?
|
Support Vector Machine | 1 | 2011 | 6 | 0.030 |
Why?
|
Presenilin-1 | 1 | 2010 | 7 | 0.020 |
Why?
|
Gels | 1 | 2010 | 9 | 0.020 |
Why?
|
Smad Proteins | 1 | 2010 | 6 | 0.020 |
Why?
|
Metabolism | 1 | 2010 | 9 | 0.020 |
Why?
|
Nitriles | 1 | 2010 | 13 | 0.020 |
Why?
|
Chromatography, Liquid | 1 | 2010 | 24 | 0.020 |
Why?
|
Amyloid beta-Protein Precursor | 1 | 2010 | 22 | 0.020 |
Why?
|
Drug Synergism | 1 | 2010 | 63 | 0.020 |
Why?
|
Triazoles | 1 | 2010 | 29 | 0.020 |
Why?
|
Bone Matrix | 1 | 2010 | 28 | 0.020 |
Why?
|
Administration, Oral | 1 | 2010 | 140 | 0.020 |
Why?
|
Models, Animal | 1 | 2010 | 126 | 0.020 |
Why?
|
Antipsychotic Agents | 1 | 2010 | 82 | 0.020 |
Why?
|
Carrier Proteins | 1 | 2010 | 97 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2011 | 153 | 0.020 |
Why?
|
tau Proteins | 1 | 2010 | 202 | 0.020 |
Why?
|
Proteoglycans | 1 | 2010 | 337 | 0.020 |
Why?
|
Cells, Cultured | 1 | 2010 | 676 | 0.020 |
Why?
|
Caseins | 1 | 2008 | 1 | 0.020 |
Why?
|
Phosphopeptides | 1 | 2008 | 1 | 0.020 |
Why?
|
Manganese | 1 | 2008 | 3 | 0.020 |
Why?
|
Ovalbumin | 1 | 2008 | 8 | 0.020 |
Why?
|
Aluminum | 1 | 2008 | 11 | 0.020 |
Why?
|
Iron | 1 | 2008 | 22 | 0.020 |
Why?
|
Serum Albumin | 1 | 2008 | 24 | 0.020 |
Why?
|
Aging | 1 | 2018 | 1593 | 0.020 |
Why?
|
Titanium | 1 | 2008 | 209 | 0.020 |
Why?
|
DNA Primers | 1 | 2004 | 51 | 0.020 |
Why?
|
Antigens, CD | 1 | 2004 | 99 | 0.020 |
Why?
|
Drug Stability | 1 | 2002 | 9 | 0.010 |
Why?
|
Stereoisomerism | 1 | 2002 | 10 | 0.010 |
Why?
|
Biophysical Phenomena | 1 | 2002 | 29 | 0.010 |
Why?
|
Basement Membrane | 1 | 2002 | 12 | 0.010 |
Why?
|
Biophysics | 1 | 2002 | 38 | 0.010 |
Why?
|